Day One Biopharmaceuticals
DAWN
DAWN was delisted on the 22nd of April, 2026.
172 hedge funds and large institutions have $603M invested in Day One Biopharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 54 increasing their positions, 61 reducing their positions, and 33 closing their positions.
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
48% more call options, than puts
Call options by funds: $641K | Put options by funds: $432K
8% more capital invested
Capital invested by funds: $561M → $603M (+$42.3M)
3% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 33
1% less funds holding
Funds holding: 174 → 172 (-2)
1.6% less ownership
Funds ownership: 85.16% → 83.57% (-1.6%)
11% less repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 61
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$23.2M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$10.5M |
| 3 |
MCO
MAK Capital One
New York
|
+$9.97M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$9.52M |
| 5 |
DM
Deerfield Management
New York
|
+$6.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$13.7M |
| 2 |
Pictet Asset Management
Carouge,
Switzerland
|
-$9.29M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.57M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.16M |
| 5 |
BlackRock
New York
|
-$5.7M |
DAWN Hedge Fund Activity: Q3 2025 in Review
172 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q3 2025, worth a combined $603M — up 7.5% from $561M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of DAWN and 32 opened new positions — a net loss of 1 holder — while 61 trimmed existing stakes and 54 added.
The largest buyer was Rubric Capital Management (New York), opening a new position worth an estimated $23.2M. The largest seller was Polar Capital Holdings, exiting entirely with an estimated $13.7M sold.
- 172 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q3 2025, down from 174 in Q2 2025.
- Funds reported $603M of Day One Biopharmaceuticals stock for Q3 2025, up 7.5% quarter-over-quarter.
- 32 funds opened new Day One Biopharmaceuticals positions in Q3 2025 and 33 closed out, a net change of -1 holder.
- The largest Day One Biopharmaceuticals buyer in Q3 2025 was Rubric Capital Management (New York), an estimated $23.2M added.
- The largest Day One Biopharmaceuticals seller in Q3 2025 was Polar Capital Holdings, an estimated $13.7M sold.
Based on aggregated 13F filings for Q3 2025.